New Antidiabetic Medications
|
|
- Buck Robinson
- 5 years ago
- Views:
Transcription
1 New Antidiabetic Medications A/Prof Harvey Newnham Director of General Medicine Clinical Program Director Emergency and Acute Medicine, Alfred Health, Melbourne 5 th May 2013
2 Diagnosed Diabetes USA Adults y.o. <3% to >7% last 20 years Polonsky K, NEJM 2012;367:1332
3 Synopsis Why is treatment of diabetes so complicated? What are the anti-hyperglycaemic agents and how do they work? Practical considerations - side effects, important drug interactions The future better agents, more evidence
4 Complexity No perfect solution Pathophysiology incompletely understood Glycaemic targets controversial Microvascular vs macrovascular Multiple approaches Huge market Consensus rather than evidence-based Patient-centred i.e. individualised approach From Polonsky K, n engl j med 367;14
5 Patient related factors Inzucci S et al, Diab. Care, Vol 35, June 2012
6 Antidiabetic medications Interfere with pathophysiological defects Hepatic glucose output: fasting and postprandially Insulin-stimulated glucose disposal (esp skeletal muscle) Renal threshold for glucose disposal in urine Insulin resistance Abnormal islet cell function (reversible: cf bariatric surgery) Incretin system dysfunction (GLP-1, GIP) Excess gluconeogenesis from increased FFA delivery to the liver Modify physiology of appetite Modify nutrient absorption &/or excretion
7 Treatment of T2DM Insulin resistance Diet, weight loss Exercise Thiazolidenediones (Metformin) Incretin Dysfunction GLP-1 Agonists/analogues DPP-IV inhibitors (Injectable amylin analogues: Pramlintide) Hepatic glucose production Metformin Insulin Islet dysfunction Insulin secretagogues Sulfonylureas, Insulin Renal glucose excretion Sodium glucose co-transporter 2 inhibitors Appetite/CHO absorption α-glucosidase inhibitors Anti-obesity agents Xenical, Phentermine/topiramate Locaserin Bariatric surgery
8 Generic and Trade Names Sulfonylureas Gliclazide: Glyade, Nidem, Diamicron (MR = slow release) Glipizide: Melizide, Minidiab Glimepiride: Aylide, Diapride, Dimirel, Amaryl, Glibenclamide (Glyburide): Glimel, Daonil Biguanides: Metformin Diaformin, Formet, Glucobete, Glucophage, Diabex, Metex XR (XR = extended release)
9 Generic and Trade Names Alpha glucosidase inhibitors Acarbose:Glucobay Thiazolidinediones Pioglitazone, Actos, Acpio, Pizaccord, Prioten, Vexazone DPP-4 inhibitors Linagliptin: Trajenta Saxagliptin: Onglyza Sitagliptin: Januvia Vildagliptin: Galvus Exenatide Byetta Sodium glucose co-transporter 2 inhibitors Canagliflozin (Invokana)
10 Combinations Metformin + Glibenclamide: Glucovance Sitagliptin + Metformin: Janumet Rosiglitazone + Metformin: Avandamet Vildagliptin + Metformin: Galvumet
11 Insulins Short acting Ultrashort acting analogues: Insulin aspart: NovoRapid Insulin glulisine: Apidra Insulin lispro: Humalog Regular (neutral): Actrapid, Humulin R Intermediate acting Isophane: Humulin NPH, Protaphane Combinations Isophane + neutral: Humulin 30/70, Mixtard 30/70, Mixtard 50/50 Lispro + Lispro protamine: Humalog Mix25, Humalog Mix50 Aspart + Aspart protamine: Novomix 30 Long acting Insulin Detemir: Levemir Insulin Glargine: Lantus
12 Biguanides Metformin Activates AMP-kinase Decreases hepatic glucose output First line agent for T2DM UKPDS showed cardioprotective effects May improve stable heart failure outcomes No weight gain or hypoglycaemia Concerns Lactic acidosis risk (small) Esp if severe CCF, PVD, renal failure, haemodynamic instability, extreme old age or pulmonary disease GIT side effects of anorexia, nausea, cramps problematic in hospital/fasting patients May increase nephrotoxicity of iodinated contrast Vitamin B12 deficiency
13 Insulin secretagogues Sulfonylureas gliclazide, glimepiride, glipizide, glibenclamide/glyburide Close K ATP channels on β-cells Reduce microvascular complications Concerns CVD from UGDP May impair ischaemic preconditioning (cease in ACS pts) No consistent evidence of detrimental effect at clinical level although some suggestive studies» Direct angioplasty SU independently associated with increased hospital mortality» Post MI SU use appears to be predictor of new coronary events in the elderly (ave age 80) Long duration of action makes titration of inpatient control difficult hypoglycaemia risk if CHO interrupted Weight gain Limited durability of effect Review by Clement S et al Diabetes Care 2004;27:553
14 PPAR-γ agonists (Insulin sensitisers) Thiazolidinediones (Glitazones) Pioglitazone, [Rosiglitazone] Increases insulin sensitivity No hypoglycaemia Good durability May decrease CVD events (Pioglitazone - ProACTIVE) Concerns Increases intravascular volume Exacerbate CCF Peripheral oedema Weight gain Bone fractures Bladder cancer Negligible effect on CAD in high risk patients (may help post-stent restenosis) Slow onset of action don t help with inpatient control
15 α-glucosidase Inhibitors Acarbose (Precose/Glucobay), Miglitol (Glyset), Voglibose Culinary mushroom (Maitake [Grifola frondosa]) natural inhibitor Slows intestinal CHO digestion/absorption No hypoglycaemia, reduced postprandial glucose May reduce CVD events (STOP-NIDDM) Concerns Modest efficacy Flatulence, diarrhoea Frequent dosing required (tds)
16 Incretins Oral glucose has greater effect on insulin release than IV Glucagon-Like Peptide-1 (GLP-1) From L-cells of small intestine Decreased in T2DM and abnormally regulated in T1DM Stimulates glucose-dependent insulin release from pancreas Metabolised by dipeptidyl peptidase-4 (DPP-4) enzyme Restores both first phase and second phase insulin response to glucose Slows gastric emptying Inhibits inappropriate post-meal glucagon release Reduces food intake From Kathleen Dungan UpToDate 2013
17 Incretin Mimetic Agents - Injectable GLP-1 Receptor Agonists Exenatide (53% homology with GLP-1), exenatide ER, liraglutide (97% homology) Action Increase glucose-dependent insulin secretion Decrease glucagon Slow gastric emptying Increase satiety No hypoglycaemia Weight reduction Preserves B-cell mass May be helpful in cardiomyopathy Concerns Nausea, vomiting, diarrhoea 10-40% Pancreatitis? Injectable (Exenatide: twice daily, once weekly, Liraglutide daily) Most effective in patients who are eating
18 Incretin Mimetic Agents - Oral Dipeptidyl peptidase-4 (DPP-4) inhibitors Sitagliptin, linagliptin, saxagliptin, vildagliptin, alogliptin Action Increases postprandial incretins GLP-1 and GIP. Increase glucose dependent insulin secretion Decrease glucagon secretion No hypoglycaemia Well tolerated, no weight gain Concerns Only effective in patients who are eating Care in renal dysfunction Modest efficacy Urticaria/angioedema Pancreatitis?
19 Amylin Mimetics Pramlintide Activates amylin receptor (Amylin is peptide from B-cells) Decreases glucagon, Slows gastric emptying, Increases satiety Reduces postprandial glucose Weight reduction Concerns Used in T1DM Modest efficacy Nausea, vomiting Frequent dosing Injectable
20 Sodium glucose co-transporter 2 (SGLT2) inhibitors SGLT2 Receptor in proximal tubule mediates reabsorption of 90% of filtered glucose Effect independent of B-cell function and insulin sensitivity Canagliflozin (Invokana), dapagliflozin, Promotes weight loss, lowers systolic blood pressure Low risk of hypoglycaemia Concerns Limited safety and efficacy data (3 rd line agent only) Side effects of UTI, vaginal yeast infections 11% (due to glycosuria), perhaps postural dizziness
21 Other drugs Non-sulfonylurea insulin secretagogues Metiglinides repaglinide Short action, could be useful. Hypoglycaemia, weight gain, frequent dosing Reduces myocardial ischaemic preconditioning Bile acid sequestering resins Colesevelam May decrease HGO and increase incretins No hypoglycaemia, reduces LDLc Modest effectiveness, constipation, increases TG Increases absorption of other agents Bromocriptine Modulates hypothalamic regulation of metabolism Increases insulin sensitivity No hypoglycaemia, may reduce CVD Concerns Modest efficacy, dizziness, syncope, nausea, fatigue, rhinitis
22 Inzucci S et al, Diab. Care, Vol 35, June 2012
23 Treatment escalation algorithm for T2DM Healthy eating & exercise Metformin Add sulfonylurea Add basal Insulin Add Incretin mimetic DPP-4 inhibitor or GLP-1 agonist Consider adding Incretin mimetic Acarbose TZD Intensify insulin therapy Basal-bolus or mixed regimen Continue metformin Consider ceasing other agents Consider bariatric surgery for high risk patients Adapted from Therapeutic Guidelines
24 Use of Antidiabetic Drugs in Special Cases Cardiac Renal Hepatic Patients at risk of hypoglycaemia
25 Coronary ischaemia Metformin probably beneficial for CVD outcomes Any drug: Avoid hypoglycaemia exacerbates ischaemia and may cause arrhythmias Relevance re adverse effects of sulfonylureas on CHD unproven Piolglitazone may reduce CVD events (don t use if CCF) GLP-1 receptor agonists and DPP-4 inhibitors may improve CVD risk factors AGIs may reduce CVD events
26 Cardiac failure Avoid thiazolidinediones Avoid metformin in severe heart failure
27 Chronic kidney disease 20-30% of patients with diabetes have egfr<60 ml/min Increased risk of hypoglycaemia Consider dose reductions and care with fluid balance Metformin has lactic acidosis risk egfr <30 ml/min avoid egfr <45 ml/min low dose only Sulfonylureas have significant renal clearance: dose adjust avoid glibenclamide (glyburide) Repaglinide can be used in CKD DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin renally cleared and need dose reduction. linagliptin hepatic metabolism GLP-1 agonists Exenatide contraindicated if egfr<30ml/min. Liraglutide drug levels unaffected by renal disease.
28 Liver disease Hepatic steatosis common in diabetes Pioglitazone may improve steatosis Avoid if ALT >2.5 x ULN Sulfonylureas may have hepatic side effects Incretin mimetics used in mild liver disease but avoid if history of pancreatitis Use insulin if advanced liver disease
29 Troublesome hypoglycaemia Potential cause of brain dysfunction Higher risk in elderly Dysrhythmias, falls, delirium Aspiration in sleep Loss of confidence Association with mortality (ACCORD) Use agents with low risk of hypoglycaemia Avoid sulfonylureas
30 Important drug interactions CYP2C9 polymorphisms influence sulfonylurea, glitinides and TZD metabolism Repaglinide and TZD concentration increased by gemfibrozil Sulfonylureas Enhance warfarin effect and vice versa Hypoglycaemic effect enhanced by quinolone antibiotics Metformin Carbonic anhydrase inhibitors enhance risk of lactic acidosis Iodinated contrast agents and nephrotoxicity DPP-4 inhibitors Increase risk of angioedema with ACE inhibitors Exenatide decreases OCP concentration and enhances warfarin effect
31 Holstein, A et al Expert Opin. Drug Metab. Toxicol. (2012) 8(12):
32 The future Establish: Cardiovascular and total mortality outcomes with different agents, combinations and treatment algorithms Comparative glycaemic effects Quality of life outcomes Durability of effectiveness (β-cell preservation) Role of pharmacogenetics
33 Other potential targets! Ranolazine Na channels in β-cells Inhibits fatty acid oxidation Selective PPARγ modulators SGLT-1 inhibitors Fructose 1,6 bisphosphatase inhibitors Glucokinase activators 11β hydroxysteroid dehydrogenase inhibitors Protein tyrosine phosphatase 1B inhibitors Acetyl-CoA carboxylase-1 and -2 inhibitors Glucagon receptor antagonists
34 References Inzucchi SE et al, Diabetes Care 2012:35;1364 Inzucchi SE and McGuire DK, Circulation 2008: 117:754 Holstein A et al, Expert Opinion Drug Metabolism and Toxicity 2012:8; 1549 Polonsky KS, NEJM 2012:367:1332 UpToDate 2013
35 The End
What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationType 2 Diabetes Mellitus hypoglycaemic agents
Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationOral and Injectable Medication Options for Diabetes Treatment
Oral and Injectable Medication Options for Diabetes Treatment Presented by: Dr. Daphne E. Smith, Pharm.D., CDE Clinical Assistant Professor/Clinical Pharmacist-University of Illinois at Chicago College
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationPhysician Drug Reference Chart for Diabetes Antidiabetic Medications
Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationNon-Insulin Diabetes Medications Summary
Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More information9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options
9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationDiabetes Mellitus. Intended Learning Objectives:
Intended Learning Objectives: Diabetes Mellitus 1. Compare and contrast the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines. 2. Assess the
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationPERIOPERATIVE DIABETES GUIDELINE
PERIOPERATIVE DIABETES GUIDELINE This Guideline does not replace the need for the application of clinical judgment in respect to each individual patient. Background Diabetes mellitus is estimated to affect
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationType. Diabetes Drugs. A Review
Type Diabetes is a common diagnosis for home care patients. Diabetes drugs are now available that target the multiple defects of metabolism that characterize Type 2 diabetes. Understanding the wide variety
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationType 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18
Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 No conflicts of interest Objectives for this talk Update on non-insulin drug therapy fro type 2 DM Appropriate use of insulin in type 2 DM ADA
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationAnti-Diabetic. Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin. Exocrine gland that produces digestive enzymes.
Anti-Diabetic The pancreas : Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin Exocrine gland that produces digestive enzymes. The peptide hormones are secreted from cells
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationDiabetes Treatment Guidelines
Diabetes Treatment Guidelines For more comprehensive information about current approaches to the diagnosis and treatment of diabetes, visit the American Diabetes Association Standards of Medical Care 2018
More information1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime
Disclosures Current Diabetes Medications None Claire Baker, M.D. Diabetes & Endocrine Associates January 24, 2018 Objectives Identify categories of diabetes medications Understand the pharmacology of diabetes
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationDiabetes 2016: Strategies for achieving optimal diabetes control
PHASE Safety Net Community Benefit Diabetes 2016: Strategies for achieving optimal diabetes control Presented by: Lisa Gilliam, MD, PhD Clinical Leader Diabetes Program Kaiser Permanente Northern California
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationDiabetes, Type 2 Management
CLINICAL GUIDELINE Diabetes, Type 2 Management A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know
Non Insulin Treatment of Type 2 Diabetes: What the PCP Needs to Know Martin J. Abrahamson, MD Senior Vice President for Medical Affairs Joslin Diabetes Center Associate Professor of Medicine Harvard Medical
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationInpatient Diabetes 20/01/2015. What should I do? Hyperglycaemia why does it matter? Why are the BSLs unstable? BSL parameters
Hyperglycaemia why does it matter? Inpatient Diabetes Angela Sheu Endocrine Registrar St George Hospital Hyperglycaemia at admission is a predictor of mortality May be part of stress response (eg post
More information9/16/2013. Sherwin D Souza, M.D.
Sherwin D Souza, M.D. Burden of disease in 2013 Type 2 DM Glucose Management Goals-understand the new guidelines by ADA/ AACE Drugs available for management of diabetes in 2013 (non insulin and insulin
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having an OGD or Bronchoscopy This guidance is provided to assist with your preparation for your endoscopic procedure. If you feel unclear about how
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More information